- Daiichi Sankyo Co Ltd (OTC:DSKYF) and AstraZeneca plc (NASDAQ: AZN) have dosed the first patient in DESTINY-Gastric04, Phase 3 trial of Enhertu (trastuzumab deruxtecan) for gastric or gastroesophageal junction (GEJ) adenocarcinoma.
- The trial will evaluate the safety and efficacy of Enhertu compared to ramucirumab/paclitaxel combination therapy in patients with HER2 positive metastatic or unresectable gastric or GEJ adenocarcinoma with disease progression on or after a trastuzumab-containing regimen.
- The primary endpoint of the trial is overall survival.
- Secondary endpoints include investigator-assessed progression-free survival, objective response rate, duration of response, disease control rate, safety, pharmacokinetics, and immunogenicity.
- The study will enroll approximately 490 patients.
- Price Action: AZN shares are down 1.15% at $59.08 during the market session on the last check Thursday.
Archer-Daniels-Midland Q2 Earnings Top Estimates
Archer-Daniels-Midland Co (NYSE:ADM) reported second-quarter FY22 sales growth of 19% year-on-year to $27.28 billion, beating the consensus of $25.16 billion. Adjusted…
